Cambridge biotech startup seeking to repurpose Vioxx raises $5M

Tremeau Pharmaceuticals, a Cambridge biotech startup that is seeking to repurpose the controversial Merck& Co. arthritis drug Vioxx as a treatment for joint pain caused by hemophilia, has closed its first equity round. Tremeau, which was founded last year, announced Thursday that it has raised $5.2 million in equity financing, although it did not disclose the investors that participated. The six-employee company said the funding would be used to advance the drug — whose generic name is rofecoxib…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news